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Introduction
• Upwards of 40% of transplant recipients are non-adherent to 
their medications3
• More specifically, CF patients are more than 50% non-
adherent to treatment regimens5
• Non-adherence often results in rejection, and therefore can 
diminish the long-term survival and outcomes of 
transplantation4
• Despite high non-adherence rates, post-liver transplant graft 
survival of CF patients is comparable to that for other 
indications of pediatric liver transplantation1
• Patient survival after liver transplantation for CF patients was 
lower, but mortality was not attributed to graft failure2
Introduction
• Non-adherence is high in the CF population
– Non-adherence is best estimated by the Medication Level Variability 
Index (MLVI)
• Graft loss from rejection is not increased
• We sought to examine the relationship between adherence




– Is there a difference between adherence, measured by
Medication Level Variability Index (MLVI), and biopsy 
proven graft rejection rates in pediatric liver transplant 
recipients with CF compared to those without CF ? 
• Hypothesis
– We hypothesize that MLVI is higher and rejection rates are 
lower in subjects with CF
Approach & Results
• Study design: Retrospective medical chart review 
• Population: 9 pediatric CF liver transplant recipients 
• Comparison Group: 9 non-CF pediatric liver transplant 
recipients 
• Outcome: Medication adherence measured by Medication
Level Variability Index (MLVI) and liver biopsy-proven graft 
rejection 
• Data source and collection: EPIC medical records from 
Children’s Hospital of Philadelphia patients between 1995 and 
2018 to find medication levels (MLVI) and liver biopsy results 
(when relevant) 
• Rationale: A retrospective chart review was most appropriate 
given the sample size and measured outcomes 
Approach & Results
• Analysis: An unpaired t-test was performed to determine if 
there was a difference in MLVI between the two groups, and 
liver biopsy reports were used to determine rates of rejection
• Findings:
– There was a trend for higher MLVI in the CF group, 
however, this did not reach statistical significance 
comparing MLVI for the CF group (M=3.40; SD= 1.60) and 
non-CF group (M=2.71; SD= 0.77); t(16)=1.15; p=0.26
– 2 subjects in the CF group (22%) and 3 subjects (33%) in 
the non-CF group had rejection on liver biopsy
– When comparing rates of biopsy-proven rejection in CF 
and controls with MLVI >2 , 14% of those with rejection 
were CF subjects and 13% were control subjects 

A. Normal portal tract and 
central vein with zones of 
the hepatic lobule labeled
B. Portal tract with features of 
rejection including mixed 
lymphocytic and eosinophilic 
infiltrate of a portal vein (small 
arrow) and damaged bile duct 
(large arrow)A. https://webpath.med.utah.edu/LIVEHTML/LIVER003.htmB. https://www.researchgate.net/figure/Histological-changes-seen-in-a-biopsy-with-acute-
cellular-rejection-in-a-patient-with_fig2_221732800l
Conclusions
• These results show adherence to immunosuppressive 
medications (as reflected by MLVI) and rates of biopsy-proven 
rejection are not statistically different between CF and non-CF 
liver transplant recipients
• Small sample size limits the strength of this study 
• MLVI has been associated with increased rate of rejection, 
however the CF population may differ from this expectation 
due immune activity from chronic lung inflammation and is 
worthy of further study
Future Directions
• Further study with a multi-center cohort may 
reveal important differences in rejection risks 
in CF
• Furthermore, study on socioeconomic factors 
that may influence medication adherence and 
rejection rates is needed
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